GlycoMimetics reports data from Phase III AML treatment trial
The study did not show a statistically significant improvement in overall survival after treatment with the uproleselan regimen.
The study did not show a statistically significant improvement in overall survival after treatment with the uproleselan regimen.
The FDA granted de novo classification to the Symani Surgical System for soft tissue manipulation in microsurgery in April 2024.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
“Defensibility” key for AI-centric small biotechs seeking investment
Klineo wins €2m to advance AI patient recruitment platform
Hyperfine starts enrolment in portable imaging workflow study
Acarix starts clinical workflow study for its AI-powered cardiac diagnostic